* MacroGenics Inc reported quarterly adjusted earnings of 90 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 28 cents. The mean expectation of ten analysts for the quarter was for earnings of 21 cents per share. Wall Street expected results to range from -89 cents to 81 cents per share.
* Revenue rose 964.8% to $110.71 million from a year ago; analysts expected $76.12 million.
* MacroGenics Inc's reported EPS for the quarter was 90 cents.
* The company reported quarterly net income of $56.31 million.
* MacroGenics Inc shares had risen by 12.5% this quarter and lost 61.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 71% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for MacroGenics Inc is 8.00 This summary was machine generated from LSEG data November 6 at 04:41 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.21 0.90 Beat
Jun. 30 2024 -0.59 -0.89 Missed
Mar. 31 2024 -0.64 -0.84 Missed
Dec. 31 2023 -0.15 -0.75 Missed
Comments